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Telomerase is a ribonucleoprotein that synthesizes the repeating
sequence (TTAGGG) n in human chromosomal ends (Morin,
1989). This protein is thought to be essential for the acquisition of
cellular immortality, because of its ability to overcome the reduc-
tion of chromosomal ends that occurs normally in somatic cells
during cell divisions (Allsopp et al, 1992; Counter et al, 1992;
Bodnar et al, 1998). After the advent of the telomeric repeat ampli-
fication protocol (TRAP) assay, telomerase activity was revealed
in many human cancers, and its association with carcinogenesis as
well as cellular immortality was postulated (Kim et al, 1994).
Human hepatocellular carcinoma (HCC) develops mainly in
liver cirrhosis, which consists of numerous regenerative nodules.
The existence of large regenerative nodules frequently makes the
accurate diagnosis of small HCC difficult. Therefore, useful
markers for the diagnosis of HCC have been sought. We have
previously reported that telomerase activity was found in 84% of
the HCCs examined, demonstrating the usefulness of examining
telomerase activity in the differential diagnosis of HCC (Nouso et
al, 1996).
Recently, three components of the telomerase were cloned;
human telomerase RNA component (hTERC), human telomerase-
associated protein 1 (hTEP1) and human telomerase reverse tran-
scriptase (hTERT) (Feng et al, 1995; Harrington et al, 1997;
Nakamura et al, 1997). Of the three components, hTERC
expression has been observed in both telomerase-positive and 
-negative tissues, and no close correlation between the hTERC
expression and the telomerase activity was reported, although
hTERC contains the essential template region specifying the
addition of telomerase sequence (Feng et al, 1995; Avilion et al,
1996). The other protein components are thought to be crucial for
the regulation of telomerase activity, since hTERT has been
proved to be the catalytic core protein component of telomerase
and hTEP1 is a putative regulator domain of which post-transla-
tional modification is closely related with telomerase activity in
the mouse homologue (Nakamura et al, 1997; Nakayama et al,
1997, 1998; Bodnar et al, 1998).
In the present study, we semiquantified the mRNA expressions
of hTEP1 and hTERT, and the telomerase activity in human liver
tissues to examine the regulatory mechanisms of telomerase in
human liver diseases, and analysed whether these components are
useful markers for telomerase activation in clinical samples
including 21-gauge (21-G)-needle biopsied specimens.
MATERIALS AND METHODS
Patients and samples
Twenty-three surgically resected HCCs (11 well-, 11 moderately-,
one poorly differentiated), and the corresponding adjacent non-
cancerous liver tissues (ten liver cirrhosis, 13 chronic hepatitis)
were analysed (Table 1). Of the 23 patients, three (13%) were
female, and the patients’ ages ranged from 38 to 75 years (mean =
62.7 years). Three patients (13%) were positive for hepatitis B
virus surface antigen, 19 patients (82.6%) were positive for
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for both viral markers. Alpha-fetoprotein (AFP) and protein
induced by vitamin K absence-II (PIVKA-II) were measured by
enzyme immunoassay. The normal ranges of AFP and PIVKA-II
are less than 10 ng ml–1 and 100 mAU ml–1 respectively. Each
tissue sample was bisected; half of the tissue was examined for
histological diagnosis, and the other half was stored at –80°C until
used for reverse transcription-polymerase chain reaction (RT-
PCR) and TRAP assay. Thirteen tumour samples (ten HCCs and
three dysplastic nodules) were obtained by aimed tumour biopsies
with 21-G needles (Table 2). The tumours were biopsied twice and
analysed for both histological diagnosis and hTERT mRNA
expression. The histological diagnosis of liver tumours was made
according to the criteria outlined by International Working Party
(1995). Informed consent was obtained from all patients for the
experimental use of the samples.
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Table 1 Telomerase activity and expression of hTERT and hTEP1 in surgically resected HCC
No.of HCC Non-cancerous AFP PIVKA-II Telomerase hTERT hTEP1a
cases Age (years)/Sex Differentiation Size (cm) liver (ng ml–1) (mAU ml–1) T NT T NT T NT
1 56/M Moderate 4.3 LC (C) 587 150 ++ + ++ + 0.50 1.94
2 61/M Moderate 2.0 CH (C) 309 118 ++ – ++ – 1.10 1.30
3 75/F Moderate 3.5 CH (C) 104 8 ++ – ++ – 1.11 1.47
4 64/M Well 3.5 CH (C) 9.7 112 + + ++ + 0.74 1.41
5 62/F Well 2.7 LC (C) 7.5 0 ++ – ++ + 2.51 2.01
6 57/M Well 2.7 CH (C) 10.8 38 + – + – 1.84 1.59
7 68/M Well 3.0 LC (C) 3.1 225 + – + – 0.89 0.72
8 55/M Poor 10.0 CH (B) 40000 656 + – ++ – 1.80 1.42
9 60/M Well 2.5 LC (C) 893 298 ++ – ++ – 1.99 1.25
10 65/M Moderate 4.5 LC (C) 443 0 ++ – ++ – 1.54 1.26
11 42/M Well 5.0 LC (B) 790 15 ++ – ++ + 1.60 1.46
12 38/M Moderate 2.5 CH (B) 11487 1914 – – + – 1.31 0.95
13 71/M Moderate 3.0 CH (C) 2111 86 ++ – ++ + 1.07 1.60
14 72/M Well 1.5 CH (C) 26.3 NI ++ + + – 1.31 1.38
15 65/M Well 2.0 CH (C) 6.1 16 ++ + ++ – 1.38 2.18
16 67/M Moderate 2.2 LC (C) 11.4 15 ++ – ++ – 1.10 1.32
17 68/M Moderate 2.0 LC (NBNC) 14 60 ++ – ++ – 1.43 1.31
18 66/M Well 1.8 CH (C) 4.5 0 ++ – ++ – 1.38 1.42
19 70/M Moderate 1.8 CH (C) 2.5 <63 ++ + ++ + 0.54 1.49
20 68/M Moderate 1.6 CH (C) 211 <70 + – ++ – 0.84 0.93
21 64/M Well 2.0 CH (C) 20.8 0 + + + + 1.17 1.08
22 62/F Well 3.0 LC (C) 18.4 0 + – + – 1.18 1.13
23 67/M Moderate 4.5 LC (C) 29.8 NI ++ – ++ – 1.00 0.98
HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; PIVKA-II: protein induced by vitamin K absence-II; hTERT: human telomerase reverse
transcriptase; hTEP1: human telomerase-associated protein 1; T: tumorous portion; NT: non-tumorous portion; M: male; F: female; CH: chronic hepatitis;
LC: liver cirrhosis; B: positive for hepatitis B virus surface antigen; C: positive for hepatitis C virus antibody; NBNC: non-B, non-C; NI: not informative;
–: negative; +: weak; ++: strong. ahTEP1 mRNA was expressed as the ratio to 18S rRNA product.
Table 2 hTERT expression in liver tumours with biopsied with 21-gauge fine needle
No. of No. of Liver tumour Non-tumorous hTERT mRNA
cases Age (years)/Sex samples Histology Size (cm) liver in tumour
1 74/M 1 HCC (Moderate) 1.3 CH (C) +
2 70/M 2 HCC (Moderate) 1.4 LC (C) ++
3 64/F 3 DN 1.9 LC (C) +
4a 76/M 4 HCC (Moderate) 2.3 CH (C) ++
5 HCC (Well) 1.7 ++
5 65/M 6 HCC (Well) 1.1 CH (C) ++
6 65/F 7 HCC (Well) 1.0 CH (C) ++
7 60/M 8 HCC (Well) 3.1 CH (C) ++
8 67/M 9 HCC (Moderate) 1.6 LC (C) +
9 58/F 10 DN 1.5 CH (C) ++
10 75/M 11 HCC (Well) 1.0 LC (NBNC) +
11 68/F 12 DN 1.2 LC (C) +
12 74/F 13 HCC (Moderate) 4.0 LC (C) ++
hTERT: human telomerase reverse transcriptase; M: male; F: female; HCC: hepatocellular carcinoma; DN: dysplastic
nodule; CH: chronic hepatitis; LC: liver cirrhosis; C: positive for hepatitis C virus antibody; NBNC: negative for hepatitis B
virus surface antigen, negative for hepatitis C virus antibody; +: weak; ++: strong. aCase 4 had two liver tumours at the
time of biopsy.cDNA preparation and semiquantitative RT-PCR
Total RNA was extracted with RNA zolTM (TEL-TEST,
Friendswood, TX, USA) according to the manufacturer’s protocol.
cDNA was generated from 3 mg of RNA by reverse transcriptase
(RAV2, Takara, Shiga, Japan) with random hexamers as primers. To
ensure that the RNA was not degraded, a PCR assay for 30 cycles
(94°C, 1 min; 60°C, 1 min; 72°C, 1 min) with primers specific for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was carried
out on each cDNA sample.
hTEP1 expression was quantified with the QuantumRNATM
module (Ambion, Austin, TX, USA), which uses 18S rRNA as  an
internal control (Raeymaekers, 1995). AmpliTaq GoldTM (Perkin-
Elmer Applied Biosystems Japan, Chiba, Japan) was used as a DNA
polymerase to increase the fidelity of the PCR by a hot start. Briefly,
cDNA was amplified with TCAAGCCAAACCTGAATCTGAG
(residues 7483–7504) as a sense and CCCGAGTGAATCTTTC-
TACGC (residues 7726–7746) as an antisense primer in the 
presence of 18S PCR CompetimersTM (Ambion) and the 18S PCR
primer pair at the ratio of 4:6 to optimize the amplification product
of 18S rRNA (Nakamura et al, 1997). The PCR conditions were
preheating at 95°C for 12 min, followed by 35 PCR cycles (95°C, 
1 min; 54°C, 1 min; 72°C, 1 min), and a final extension at 72°C for
4 min. The amplification was in the exponential range (data not
shown). The PCR products were electrophoresed in 1% agarose gels
and stained with ethidium bromide. The intensity of the bands was
quantified by a charge-coupled device image sensor (Analytical
Imaging Station, Imaging Research, Ontario, Canada), and hTEP1
expression was expressed as the ratio to the 18S rRNA product.
We semiquantified hTERT by changing PCR cycle numbers
because the difference of the expression levels among samples was
too large to use the QuantumRNATM module. hTERT was amplified
by AmpliTaq GoldTM with a sense primer CGGAAGAGTGTCTG-
GAGCAA (residues 1784–1803) and an antisense primer GGAT-
GAAGCGGAGTCTGGA (residues 1910–1928) (Nakamura et al,
1997). The PCR conditions were preheating at 95°C for 12 min,
followed by 38 or 45 PCR cycles (95°C, 1 min; 52°C, 1 min; 72°C,
1 min 30 s) and a final extension at 72°C for 4 min. We used low
annealing temperature to increase the sensitivity. The PCR products
were electrophoresed in 1% agarose gels and stained with ethidium
bromide. We chose 38 PCR cycles for the detection of hTERT
although the products could be detected at 32 cycles in some
samples, because we could effectively differentiate the samples
with strongly positive telomerase activity from those with weakly
positive telomerase activity at 38 cycles in a preliminary experi-
ment. The samples that were positive at 38 PCR cycles, positive at
45 PCR cycles, and negative at 45 PCR cycles were denoted as
strong (++), weak (+), and negative (–) respectively.
We confirmed that no contamination of the genomic DNA
existed by treating RNA samples with deoxyribonuclease before
RT-PCR.
Telomeric repeat amplification protocol assay
The telomerase activity in the tissues was analysed by a TRAP
assay as previously described (Nouso et al, 1996). Extracted
samples that were positive at 0.6 mg (24-h exposure), positive at 
6 mg (48-h exposure), and negative at 6 mg (48-h exposure) were
denoted as strong (++), weak (+), and negative (–) respectively.
Rat myogenin sequence was used as an internal standard to detect
the existence of an inhibitor of TRAP assay.
Statistical analyses
All experiments were done in duplicate and the reproducibility
was confirmed. Statistical analyses were performed with c2 test,
Student’s t-test, and Fisher’s exact probability test. A P-value of 
P < 0.05 was considered significant.
RESULTS
The transcripts of hTEP1 and hTERT and the telomerase activity
were examined (Figure 1 and Table 1). Telomerase activity was
detected in 22 of 23 HCC samples and six of 23 non-cancerous
liver tissues. Sixty-five per cent (15/23) of HCCs showed strong
telomerase activity, but none of the non-cancerous tissues did. No
evidence of an inhibitor in TRAP assay was proved in all samples
examined.
hTEP1 mRNA was expressed in all samples. The expression
was not significantly different among the chronic hepatitis, liver
cirrhosis, and HCC samples (Table 3). The difference of tumour
size and viral markers did not correlate with hTEP1 expression;
however, the hTEP1 expression in the well-differentiated 
HCC was higher than that in the moderately differentiated 
HCC (P < 0.05, Student’s t-test). The hTEP1 expression in the
samples with negative, weak, and strong telomerase activity was
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Figure 1 The expression of telomerase activity, human telomerase-
associated protein 1 (hTEP1), human telomerase reverse transcriptase
(hTERT), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in five
patients with hepatocellular carcinoma (HCC). The telomerase activity was
analysed by a telomeric repeat amplification assay. hTEP1 mRNA (lower
band) was amplified by RT-PCR and compared with the band intensities of
18S rRNA (upper band). Two different PCR cycles (38 and 45) were used for
the semiquantitation of hTERT mRNA. Note that the telomerase activity
correlated with hTERT but not with hTEP1. CH: chronic hepatitis; LC: liver
cirrhosis1.30 ± 0.29 (n = 18), 1.38 ± 0.29 (n = 13), and 1.30 ± 0.49 (n =
15) respectively (mean ± standard deviation), and no significant
difference was observed among the groups (Student’s t-test).
In contrast to hTEP1, the expression of hTERT mRNA was
closely related with the telomerase activity (P < 0.001, c2 test,
Table 4). The positivity of hTERT for the HCC and the corre-
sponding non-cancerous liver was 100% and 30.4% respectively
(P < 0.001, c2 test, Table 5). Seventy-four per cent (17/23) of
HCCs showed strong hTERT expression, whereas none of the non-
cancerous tissues did. Although no significant difference was
observed, the incidence of the strong expression in the moderately
differentiated HCC tended to be higher than that in the well-
differentiated HCC (P = 0.074, Fisher’s test), and the incidence
also tended to be higher in the HCC larger than 3 cm (P = 0.079,
Fisher’s test). Seventy-five per cent (6/8) of small HCCs (2 cm or
less in diameter) showed strong hTERT expression. The viral
marker status of HCC did not affect the positivity.
The sensitivity and the specificity of strong hTERT for the diag-
nosis of HCC was 73.9% (17/23) and 100% (23/23) respectively.
In the 21 informative samples of which the following three
markers were examined, the positivity of AFP, PIVKA-II and
strong hTERT was 71.4% (15/21), 33.3% (7/21), and 76.2%
(16/21) respectively (Table 1). The strong expression of hTERT
was observed in 83.3% (5/6) of AFP-negative HCC and in 78.6%
(11/14) of PIVKA-II-negative HCC.
The expression of hTERT was observed in all biopsied samples
examined (Table 2). The incidence of strong hTERT expression in
HCCs and in dysplastic nodules was 70% (7/10) and 33.3% (1/3)
respectively.
DISCUSSION
In the present study, we, for the first time, semiquantified hTEP1,
hTERT, and telomerase activity simultaneously in human HCC
with corresponding non-cancerous liver. We found that the expres-
sion of hTERT but not hTEP1 correlates significantly with the
telomerase activity in the human liver. Our result is consistent with
previous in vitro experiments and recent reports on human livers
including a semiquantitation study of telomerase and hTERT with
real-time PCR (Nakamura et al, 1997; Bodnar et al, 1998;
Nakayama et al, 1998; Hisatomi et al, 1999).
The diagnosis of HCC has been difficult though imaging modal-
ities have been drastically improved. Small liver nodules are now
frequently found, but many are still difficult to obtain accurate
diagnosis. For the diagnosis of small HCC, the most reliable
method currently used is a histological examination of the biop-
sied samples, which is, however, sometimes ambiguous. In the
present study, the high expression rate of strong hTERT in small
HCC and the low incidence of strong hTERT expression in non-
cancerous liver were observed. In addition, the high incidence of
strong hTERT expression was observed even in serum AFP-nega-
tive or PIVKA-II-negative HCC; AFP and PIVKA-II are clinically
used as good markers for the diagnosis of HCC (Nakagawa et al,
1999). These findings are all beneficial for the hTERT examina-
tion in the differential diagnosis of HCC. However, one of the
three dysplastic nodules showed strong hTERT expression.
Moreover, it has been reported in a recent study that dysplastic
nodules in human livers exhibited telomerase activity at various
levels (Hytiroglou et al, 1998). The distinction between HCCs and
836 N Toshikuni et al
British Journal of Cancer (2000) 82(4), 833–837 © 2000 Cancer Research Campaign
Table 3 hTEP1 expression in HCC and corresponding non-cancerous liver
hTEP1 mRNA/18S rRNA
n (mean ± standard deviation)
HCC 23 1.28 ± 0.46
Differentiation
Well 11 1.44 ± 0.48a
Moderate 11 1.05 ± 0.31a
Poor 1 1.80
Size (cm)
≤2 8 1.14 ± 0.29
2≤3 8 1.49 ± 0.53
>3 7 1.18 ± 0.45
Viral marker
B 3 1.57 ± 0.20
C 19 1.22 ± 0.48
NBNC 1 1.43
Non-cancerous liver 23 1.37 ± 0.34
CH 13 1.40 ± 0.31
LC 10 1.35 ± 0.38
hTEP1: human telomerase-associated protein 1; HCC: hepatocellular
carcinoma; B: positive for hepatitis B virus surface antigen; C: positive for
hepatitis C virus antibody; NBNC: non-B, non-C; CH: chronic hepatitis; LC:
liver cirrhosis. aP < 0.05 (Student’s t-test).




hTERTa –1 4 2 0
mRNA + 4 8 1
++ 0 3 14
hTERT: human telomerase reverse transcriptase; HCC: hepatocellular
carcinoma; –: negative; +: weak; ++: strong. aP < 0.001 (c2 test).
Table 5 hTERT expression in HCC and corresponding non-cancerous liver
hTERT mRNA
– + ++ Positive no. (%)
HCC 0 6 17 23/23 (100)a
Differentiation
Well 0 5 6
Moderate 0 1 10




>3 0 0 7
Viral marker
B0 1 2
C0 5 1 4
NBNC 0 0 1
Non-cancerous liver 16 7 0 7/23 (30.4)a
CH 9 4 0 4/13 (30.8)
LC 7 3 0 3/10 (30)
hTERT: human telomerase reverse transcriptase; HCC: hepatocellular
carcinoma; –: negative; +: weak; ++: strong; B: positive for hepatitis B virus
surface antigen; C: positive for hepatitis C virus antibody; NBNC: non-B, non-
C; CH: chronic hepatitis; LC: liver cirrhosis. aP < 0.001 (c2 test).dysplastic nodules is clinically important but still remains difficult.
Since the number of dysplastic nodules examined was small,
further investigation will be needed to clarify whether hTERT
expression in dysplastic nodules differs from that in HCC.
In the evaluation of hTERT expression for diagnosing HCC, one
has to be careful about the ‘false-positive’ of hTERT in non-
cancerous liver. There are several possible reasons for the hTERT
expression in non-cancerous liver. We have detected weak hTERT
expression in peripheral blood mononuclear cells (data not
shown). Infiltrating lymphocytes in chronic hepatitis or cirrhotic
liver may be responsible for the hTERT expression in liver tissues.
A harbouring micrometastasis of HCC may be another possibility,
although the hTERT expression in surrounding non-cancerous
liver was not related with the differential stage of the corre-
sponding tumour in the present series.
hTEP1 has been shown to interact with mammalian telomerase
RNA and telomerase activity (Harrington et al, 1997). However,
no significant difference in the hTEP1 expression was observed
between the telomerase-positive and -negative liver samples in the
present study. Therefore, the measurement of hTEP1 expression is
not applicable in the differential diagnosis of HCC. A modification
of rat homologue of hTEP1 from p240 to p230 in accordance with
the telomerase activation was reported, so that the examinations of
the change of the molecular weight of hTEP1 might help the diag-
nosis of HCC (Nakayama et al, 1997).
We observed individual variations of hTEP1 expression and
found that the moderately differentiated HCC expressed less
hTEP1 than the well-differentiated HCC. Although this seems to
be compatible with the report that hTEP1 expression in HL60 cells
was augmented by the induction of differentiation, the reason for
the difference in HCC is presently unknown (Reichman et al,
1997).
The detection of telomerase-active cells in the tissue section has
been difficult, because most of the biopsied samples have been
fixed with formalin and embedded in paraffin for the histological
examination. Recently, a modified in situ hybridization method for
detecting hTERT mRNA using formalin-fixed paraffin-embedded
tissue was developed (Kolquist et al, 1998). Further histological
analyses of hTERT may enable us to identify telomerase-active
cells in human liver and provide us with new information about the
accurate diagnosis of HCC.
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